Chapter Nine - The Comeback Kid

CHAPTER NINE

The Comeback Kid

BY THE 1960S, Bayer had fully returned.

The war was over. The trials were over. The brand was back. Bayer relaunched itself as a modern pharmaceutical company, leaning heavily on its most famous legacy: Aspirin.

The drug was reintroduced to global markets with new energy. Marketing campaigns framed it as a trusted household staple. A symbol of relief. A piece of everyday life.

The company didn’t talk about Heroin. Or Auschwitz. Or IG Farben. It didn’t have to. The world was moving on and Bayer moved with it.

Research resumed. New drugs were developed. Antibiotics, cancer treatments, birth control and pills. The company expanded into agriculture, plastics, and animal health. It started acquiring smaller firms. Building out global supply chains. Reinventing its image.

Bayer wasn’t just recovering. It was winning.

The postwar boom helped. So did the Cold War. Governments wanted innovation. People wanted convenience. The world wanted solutions, and Bayer offered them in a bottle, a capsule, and a crop.

The past was buried in technical documents and court transcripts. The present was clean packaging and forward-looking science.

By the 1980s, Bayer was once again a global force.

It had survived one of the darkest legacies in corporate history. Not by denying it. Not by confronting it. Just by outlasting the memory.

That was the trick.
And Bayer had learned it well.